Persistent Pulmonary Hypertension (PPHN) F. Hazel R. Villa, MD PL1.

Slides:



Advertisements
Similar presentations
CONGENITAL HEART DISEASE.
Advertisements

Meconium Happens: Meconium Aspiration Syndrome John Salyer RRT-NPS, FAARC, MBA Director Respiratory Therapy Seattle Children’s Hospital and Research Institute.
Acyanotic Heart Disease PRECIOUS PEDERSEN INTRODUCTION Left to right shunting lesions, increased pulmonary blood flow The blood is shunted through.
 Cardiovascular System – Heart and Blood Vessels Topics in Human Pathophysiology Fall 2011 Gilead Drug Safety and Public Health.
Persistent Pulmonary Hypertension of the Newborn John Salyer RRT-NPS, MBA, FAARC Director Respiratory Therapy Seattle Children’s Hospital and Research.
Neonatal Physiology Teka Siebenaler RRT Cardiopulmonary Services
Dip. Diab.DCA, Dip. Software statistics
Congenital Diaphragmatic Hernia & Eventration Of Diaphragm
Neonatal Options for the 3100A. VIASYS Healthcare, Inc. Neonatal Options for the 3100A Early Intervention Pro-Active Rescue.
Neonatal Respiratory Distress
Patent Ductus Ateriosis PDA Muhammad Syed MD Heart.
PATENT DUCTUS ARTERIOSUS By: Nicole Stevens. Patent Ductus Arteriosus is a functional connection between the pulmonary artery and the descending aorta.
Meconium Aspiration Syndrome Edited May  PO 2 L --> R ductus arteriosus shunt Ventilation Remove Placenta Ductus Venosus Closes  Systemic Vascular.
Blood Flow. Due to the pressure difference of two vessel ends.
Persistent Pulmonary Hypertension of the Newborn
PULMONARY HYPERTENSION IN THE NEONATES SIMONA NICHITA 01/30/2007.
Pulmonary Hypertension and Various Treatment Options
Congenital Heart Defects
Pulmonary Hypertension
CONGENITAL DISEASES Dr. Meg-angela Christi Amores.
CONGENITAL DIAPHRAGMATIC HERNIA ( C D H ) Dr JACOB MATHEW DEPT. OF PAED. SURGERY Dr AHMED ABANAMY HOSPITAL.
Viagra ® and the Neonate Robert E. Lyle, M.D. Associate Professor of Pediatrics.
Autoregulation The Renin-angiotensin-aldosterone (RAA) system is an important endocrine component of autoregulation. Renin is released by kidneys when.
Congenital heart disease
Pulmonary Circulation Dr. Walid Daoud MBBCh, MSc, MD, FCCP Director of Chest Department, Shifa Hospital, A. Professor of Chest Medicine.
Pulmonary Hypertension. Best Method for Mx of PHTN is PREVENTION.
Newborn and Early Childhood Respiratory Disorders RT 265 Chapter 33.
Persistent Pulmonary Hypertension of the Newborn (PPHN) Fred Hill, MA, RRT.
5/98MedSlides.com1 Pulmonary (Arterial) Hypertension
Heart failure Dr Rafat Mosalli. Objectives Definition Definition Pathophysiology Pathophysiology Age specific Causes Age specific Causes Clinical pictures.
Congenital Cardiac Lesions. Overview Three Shunts of Fetal Circulation Ductus Arteriosus Ductus Arteriosus Protects lungs against circulatory overload.
Patent Ductus Arteriosus
Respiratory failure Respiratory failure is a pathological process in which the external respiratory dysfunction leads to an abnormal decrease of arterial.
PICU Resident Talk Stanford School of Medicine Pediatric Critical Care Medicine June 2014.
Shock. Shock Evaluation & Management Definition of Shock A condition that occurs when tissue perfusion with oxygen becomes inadequate. Hypoxia.
Fetal Circulation Mike Clark, M.D.. Figure (a) Day 20: Endothelial tubes begin to fuse. (b) Day 22: Heart starts pumping. (c) Day 24: Heart continues.
1. Cardiovascular system begins forming at 3 weeks
Truncus Arteriosus Seoul National University Hospital Department of Thoracic & Cardiovascular Surgery.
What is the chest x-ray finding in a L-R shunt? Differentiate pulmonary arterial from pulmonary venous congestion. Question No.4.
Mike Haines, MPH, RRT-NPS, AE-C
Good Morning and Welcome Applicants!
Differentiate Pulmonary arterial hypertension from pulmonary venous congestion.
Regional Circulation and its regulation
Cor Pulmonale Dr. Meg-angela Christi Amores. Definition Cor Pulmonale – pulmonary heart disease – dilation and hypertrophy of the right ventricle (RV)
Control of the Circulation Control of the circulation depends on a variety of mechanisms that are directly related to the specific functions performed.
CONGENITAL HEART DISEASES
Disorders of cardiovascular function. R Pulmonary Artery.
1 Special circulations, Coronary, Pulmonary… Faisal I. Mohammed, MD,PhD.
Circulatory Physiology AnS 536 Spring Development of the Circulatory System 1st functional organ system – heart is functional when embryo is 2 mm.
Department of Child Health University of Sumatera Utara
Chris Burke, MD. What is the Ductus Arteriosus? Ductus Arteriosus  Allows blood from RV to bypass fetal lungs  Between the main PA (or proximal left.
Anatomic Physiologic features cardiovascular system in infants and children. associate professor Kantemirova M.G.
Volume administration Overload Hypovolemia. Volume and the failing RV Volume overload Increased wall tension Reduced contractility.
PHARMACOLOGY OF ANTI-ANGINAL DRUGS (ID#580) Dr. Mariam Yousif Pharmacology & Toxicology Dept. November 17 th, 2014.
Special circulations, Coronary, Pulmonary…
Persistent Pulmonary Hypertension in the Newborn
Persistent Pulmonary Hypertension of the Newborn
The cardiovascular system
Persistent Pulmonary Hypertension of the Newborn
Congenital Heart Disease
NEONATAL TRANSITION.
Meconium aspiration syndrome
Physiology of the Kidney 201
Cardiopulmonary Interactions in PPHN
Endothelium-derived mediators: the vasodilators prostacyclin (PGI2) and nitric oxide (NO) and the vasoconstrictor endothelin (ET-1). Endothelium-derived.
CARDIOVASCULAR 5 BLOOD FLOW.
Patent Ductus Arteriosus
Antianginal Drugs.
Etiology and pathophysiology of persistent pulmonary hypertension of the newborn (PPHN). Etiology and pathophysiology of persistent pulmonary hypertension.
Pulmonary Hypertension (PH)
Presentation transcript:

Persistent Pulmonary Hypertension (PPHN) F. Hazel R. Villa, MD PL1

Objectives to review the fetal,transitional and postnatal circulation in relation to PPHN to review the fetal,transitional and postnatal circulation in relation to PPHN To understand the pathophysiology of PPHN as it applies to clinical manifestations and management To understand the pathophysiology of PPHN as it applies to clinical manifestations and management

Pulmonary vessels VASOCONSTRICTORS (Maintain high fetal PVR) Norepinephrine A-adrenergic stimulation HypoxiaEndothelinThromboxanesLeukotrienes Platelet activating factor PGF2aVASODILATORS (Decrease PVR during transition) PGI2, PGD2, PGE2 Nitric oxide Cyclic GMP Cyclic AMP OxygenAdenosineBradykinin

Fetal circulation

pO2, PGI2, NO pO2, PGI2, NO ADMA -- competes with arginine ADMA -- competes with arginine inhibit NOS inhibit NOS Vasoconstriction Vasoconstriction

Postnatal circulation

Transitional circulation

Transitional to postnatal At birth At birth increase in NO, NOS-  cGMP increase in NO, NOS-  cGMP increase guanylate cyclase-  cGMP increase guanylate cyclase-  cGMP increase in PGI2 (effect of estrogen)  cAMP increase in PGI2 (effect of estrogen)  cAMP DDAH metabolizes ADMA DDAH metabolizes ADMA Vasodilatation Vasodilatation

Transitional to postnatal At birth At birthventilation increase pulmonary blood flow Oxygenation Oxygenation

Transitional to postnatal Oxygen- stimulates NOS, COX1 Oxygen- stimulates NOS, COX1 Pulmonary blood flow- release of NO, PGI2 Pulmonary blood flow- release of NO, PGI2 Evidence: NO-cGMP pathway is a more potent modulator of pulmonary vascular tone Evidence: NO-cGMP pathway is a more potent modulator of pulmonary vascular tone

Increase in SVR Removal of the placenta Removal of the placenta Catecholamine associated with birth Catecholamine associated with birth Cold environment Cold environment

Postnatal decrease in PVR Expansion of the lung Expansion of the lung Adequate ventilation, oxygenation Adequate ventilation, oxygenation Clearance of fetal lung fluid Clearance of fetal lung fluid

3 types of abnormalities Maladaptation Maladaptation Maldevelopment Maldevelopment Underdevelopment Underdevelopment

Maladaptation Prototype: Meconium aspiration pneumonia Prototype: Meconium aspiration pneumonia Pneumonia, RDS Pneumonia, RDS Obstruction of the airways Obstruction of the airways Chemical pneumonitis Chemical pneumonitis Release of endothelin,thromboxane  vasoconstrictors Release of endothelin,thromboxane  vasoconstrictors

Maldevelopment Prototype: Idiopathic PPHN Prototype: Idiopathic PPHN (“black lung” PPHN) (“black lung” PPHN) Vessel wall thickening Vessel wall thickening Smooth muscle hyperplasia Smooth muscle hyperplasia Cause – intrauterine exposure to NSAID Cause – intrauterine exposure to NSAID constriction of ductus arteriosus constriction of ductus arteriosus genetic genetic

Disruption of NO-cGMP pathway Disruption of NO-cGMP pathway Disruption of PGI2-cAMP pathway Disruption of PGI2-cAMP pathway Guanylate cyclase is less active Guanylate cyclase is less active Increased ROS (reactive oxygen species)  vasoconstrictor Increased ROS (reactive oxygen species)  vasoconstrictor Increased thromboxane, endothelin Increased thromboxane, endothelin Maldevelopment

Underdevelopment Prototype: Congenital diaphragmatic hernia Prototype: Congenital diaphragmatic hernia Pulmonary hypoplasia Pulmonary hypoplasia Decreased cross sectional area of pulmonary vasculature Decreased cross sectional area of pulmonary vasculature Decreased pulmonary blood flow Decreased pulmonary blood flow Abnormal muscular hypertrophy of the pulm arterioles Abnormal muscular hypertrophy of the pulm arterioles

Clinical signs and symptoms PE: PE: meconium staining meconium staining Prominent precordial impulse Prominent precordial impulse Narrow split accentuated P2 Narrow split accentuated P2 Systolic murmur LLSB Systolic murmur LLSB

Labs CXR: CDH, decreased vascular markings, parenchymal disease CXR: CDH, decreased vascular markings, parenchymal disease ECG: RV predominance, ST elevation ECG: RV predominance, ST elevation ABG: hyperoxic test (pO2 < 100 at 100% O2) ABG: hyperoxic test (pO2 < 100 at 100% O2) Pre and postductal ABG (R radial artery: umbilical artery/lower extremity) Pre and postductal ABG (R radial artery: umbilical artery/lower extremity) 10-15% saturation and or 10-15mmHg pO % saturation and or 10-15mmHg pO2

Labs Echocardiography Echocardiography Structural heart disease is determined Structural heart disease is determined R-L shunting (Ductus or FO) R-L shunting (Ductus or FO) Pulmonary arterial pressure is measured Pulmonary arterial pressure is measured

Management Oxygen 100% pO2 should be kept between 50-90mmHg (O2 saturation >90%) Oxygen 100% pO2 should be kept between 50-90mmHg (O2 saturation >90%) Correct factors promoting vasoconstriction: hypoglycemia, hypocalcemia, anemia, hypovolemia Correct factors promoting vasoconstriction: hypoglycemia, hypocalcemia, anemia, hypovolemia Optimize cardiac function (inotropic agents, volume expansion Optimize cardiac function (inotropic agents, volume expansion Mechanical ventilation Mechanical ventilation Surfactant Surfactant

Inhaled Nitric oxide- an ideal selective pulmonary vasodilator Inhaled Nitric oxide- an ideal selective pulmonary vasodilator OI of >25 OI of >25 OI=(MAP x FiO2)/pO2 x 100 OI=(MAP x FiO2)/pO2 x 100 Contraindications: CHD which are PDA dependent Contraindications: CHD which are PDA dependent (aortic stenosis, interrupted aortic arch, hypolastic heart syndrome) (aortic stenosis, interrupted aortic arch, hypolastic heart syndrome) May worsen pulmonary edema in obstructed TAPVR May worsen pulmonary edema in obstructed TAPVR Management Used to transport patient for ECMO

ECMO ECMO Goal of this treatment: Goal of this treatment: maintain adequate tissue oxygenation and maintain adequate tissue oxygenation and avoid irreversible lung injury, while PVR decreases and correcting pulm HTN avoid irreversible lung injury, while PVR decreases and correcting pulm HTN ECMO if OI is >40 ECMO if OI is >40 Management

Other Pulmonary Vasodilators Sildenafil- PDE5 inhibitor  increased cGMP Sildenafil- PDE5 inhibitor  increased cGMP Milrinone- PDE3 inhibitor  increased cAMP Milrinone- PDE3 inhibitor  increased cAMP Inhaled PGI2 Inhaled PGI2 Superoxide dismutase-superoxide scavenger  Superoxide dismutase-superoxide scavenger  Dilates pulm vessels, and increase endogenous NO Dilates pulm vessels, and increase endogenous NO

References /1427&view=print /1427&view=print /1427&view=print /1427&view=print phassociation.org/medical/.../Summer_2006/persisten t_ph_newborn.pdf phassociation.org/medical/.../Summer_2006/persisten t_ph_newborn.pdf

Thank you!